



JOINT WORKING EXECUTIVE SUMMARY

Project Title: Commissioning for Quality Metrics in Multiple Sclerosis (CQMS)

Project description:

The project aims to develop clinically-relevant quality commissioning metrics in Multiple Sclerosis (MS) for the NHS, to enable commissioners and providers to improve the quality of services delivered to MS patients and to improve patient outcomes. The project will also support the development of standardised Patient Reported Experience Measures (PREMs).

Organisations involved:

Roche Products Ltd, Blizzard Institute, Barts and The London School of Medicine and Dentistry, University of Plymouth, The Walton Centre NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, Revive MS, MS Society, MS Trust, The Healthcare Financial Management Association.

Project approach:

A multidisciplinary steering group of stakeholders (including representatives from Roche Products Ltd, patient groups, MS clinicians and a commissioner) via workshops will be responsible for the development, piloting and validation of key commissioning quality metrics and PREMs based on the best available evidence.

Expected outcomes:

Benefits to Patients:

Development of quality measures that can be audited, this will allow the ability for MS patients to provide feedback and inform the shaping of healthcare services they receive and a more positive experience of care.

Benefits to NHS:

To standardise and improve the quality of MS service delivery in the UK by developing clinically-relevant commissioning metrics and patient reported experience measures (PREMs).

Benefits to Roche:

Optimisation of quality of care for MS patients by development of system quality metrics and patient reported experience measures (PREMs). The project will provide insights into how the current service is delivered and what is most important to MS patients.

Resource Breakdown

Roche Products Ltd contribution to the Joint working project is £73,775 made up of: project management; agency organisation of meeting attendees and venues for workshop events; subsistence; travel to and from venue for five project group workshops; data analysis and medical writing support for publications.

The estimated organisations pro-rata staff contribution to the project is an estimated £65,279.

This document has been produced by Roche Products Ltd.